Objective The purpose of this study was to investigate whether isolated maternal hypothyroxinaemia (IMH) is associated with risks of small/large-for-gestational-age (SGA/LGA) infants.
Introduction
The detection of fetal growth disorders is an important goal in modern prenatal care. 1 Birthweight is often used as a proxy for fetal growth and development. 2 Large-for-gestational-age (LGA) and small-for-gestational-age (SGA) are common adverse birth outcomes that threaten the health of both mothers and their offspring, especially causing metabolic problems among the offspring later in life.
Thyroid hormones (TH) are critical for normal fetal development. 3 Fetal thyroid hormones are mainly derived from the mother until the fetus completely establishes its own thyroid function after 20 weeks of gestation. 4 Following the physiological and hormonal changes induced by pregnancy and human chorionic gonadotropin (HCG), the production and metabolism of maternal thyroid hormones also changes. [5] [6] [7] Thyroid diseases are relatively common among women of reproductive age. 8 During the past decade, the effects of thyroid dysfunction on fetal development have gained increasing attention from the scientific community, but the clinical significance of isolated maternal hypothyroxinaemia (IMH) remains unclear. Most studies have focused on the impact of IMH on child neurodevelopment, [9] [10] [11] [12] whereas a limited number of well-conducted studies have investigated the effects of IMH on fetal growth and have yielded conflicting results. For example, van Mil et al. 13 found that maternal hypothyroxinaemia is associated with larger fetal and infant head sizes. Evidence from Le on et al. 14 also showed that IMH results in higher birthweight. In contrast, Su et al. 15 found that isolated hypothyroxinaemia is related to SGA, whereas other studies found no associations between IMH and low birthweight 16 or SGA. 17, 18 Therefore, large prospective cohort studies focusing on the effects of IMH on fetal growth are urgently needed. The objective of this study was to examine whether an increased frequency of SGA/LGA infants was evident among women with IMH identified in a homogeneous population without pre-existing thyroid disease.
Methods

Study population
This prospective cohort study of pregnant women from the Ma'anshan Birth Cohort (MABC) study was designed to investigate the associations between maternal environmental exposures and birth outcomes and child development. We recruited pregnant women who presented to Ma'-shan Maternal and Child Health (MCH) clinics for their first prenatal care visit between May 2013 and September 2014. Among the 3474 pregnant women who were invited, 296 who presented with absence of live birth (n = 162), plural gestations (n = 39), thyroid disease (n = 80) or without thyroid hormone levels in both the first and second trimesters (n = 7), or without birthweight data (n = 8) were excluded from this study (shown in Supporting Information Figure S1 ). Eligible pregnant women were given a written letter explaining the purpose of the study and completed a self-administered questionnaire at their first and second visits to the Ma'anshan MCH clinic for prenatal care.
Ethical approval was obtained from the Biomedicine Ethical Committee of Anhui Medical University (Ref. No. 20131195 ). Written informed consent was obtained from all eligible women who agreed to participate in this study.
Measurement of serum thyroid profiles and definition of IMH
Maternal serum specimens were collected from the women at their first (mean = 10.01 weeks; SD 2.13) and second (mean = 25.64 weeks; SD 1.07) antenatal visits. Separated serum was stored at À80°C for subsequent biochemical analysis. Serum samples were assayed for levels of thyroid-stimulating hormone (TSH), free thyroxine (FT4), and thyroid peroxidase antibody (TPO-Ab) through electrochemiluminescence using the Cobas e411 automated immunoassay platform (Roche Diagnostics GmbH, Mannheim, Germany) in the Anhui Provincial Key Laboratory of Population Health & Aristogenics (Hefei City, Anhui Province, China) in October 2015. Two quality control samples were run daily with each assay. The coefficients of variation for the assays of these thyroid profiles ranged from 5 to 8%. TH concentrations less than the limit of detection (LOD) were assigned an LOD value by dividing by the square root of 2. 19 According to the manufacturer's instructions, TPO-Ab was considered positive at concentrations >34.0 IU/ml.
The generation and metabolism of thyroid hormones can change during pregnancy. 5 Due to variations in thyroid stimulating hormone (TSH) and free thyroxine (FT4), reference intervals are affected by many factors, and a consensus regarding the definition of IMH is lacking. 15 Different studies use different FT4 percentile cut-offs, and there is no consistency across the assays used. 3 The manufacturer did not provide trimester-specific reference ranges for TSH or FT4. Therefore, regional trimester-specific TH reference intervals from our own laboratory values were used to screen, diagnose and treat IMH during pregnancy. We defined IMH as a normal maternal TSH (2.5th-97.5th percentile) in conjunction with an FT4 lower than the 2.5th percentile at different gestational ages.
Outcome measurements
The cohort has been followed up for more than 45 months since enrolment in this study. Information on birthweight was obtained from medical records completed by the clinical midwives and obstetricians. Based on birthweight, the infants were divided into three groups: (1) SGA, defined based on the method developed by Mikolajczyk RT 20 as a birthweight lower than the 10th percentile for the gestational age-specific value of the study cohort; (2) appropriate for gestational age (AGA), defined as a birthweight between the 10th and 90th percentiles for the gestational age-specific value; and (3) LGA, defined as a birthweight greater than the 90th percentile for the gestational age-specific value. In the statistical analyses, AGA served as the reference group.
Covariates
Detailed information about the participants was obtained through questionnaires administered by trained interviewers during each trimester and comprised information on maternal demographics, pregnancy-related information and medical history, including socio-economic status (SES), maternal age, parity, vomiting in the first trimester, nutrition supplements, smoking and drinking habits, sun exposure, nutrition supplements, sleep, Chinese herb usage, delivery mode (vaginal delivery, caesarean section) and disease during pregnancy (including diabetes, epilepsy, pheochromocytoma, aldosteronism, chronic hypertension, aortic coarctation and Cushing's syndrome). At enrolment, the pre-pregnancy weight was self-reported and the maternal height was measured to calculate the prepregnancy body mass index (BMI) in kg/m 2 , and the maternal weight before delivery was obtained to calculate the gestation weight gain (GWG).
Statistical analysis
Descriptive statistics were calculated for the demographic characteristics of the mothers and their newborns. Normally distributed continuous variables were expressed as the means AE SD, and Chi-square tests and ANOVA were used to compare the means and proportions of the demographic characteristics in the SGA/LGA and AGA mother-newborn pairs.
Because the distributions of TSH were right-skewed, these variables were transformed by the natural logarithm (ln) to improve their linear relations with the outcome variables. When birthweight was treated as a continuous variable, the linear regression model was applied to calculate the regression coefficient and its 95% confidence interval (95% CI) to evaluate the effects of different indexes (TH, FT4 and TPO-Ab positivity) on this variable. After we defined the outcomes as categorical variables (SGA/ LGA), the logistic regression model was applied to calculate the odds ratios (OR) and 95% CI to assess the effect sizes of indexes (TH, FT4, TPO-Ab positivity and IMH). Adjusted covariates included maternal age, paternal age, pre-pregnancy BMI, gestational age, metabolic dysfunctions, parity, TPO-Ab positivity, delivery mode, GWG and fetal gender.
The data analyses were performed using SPSS software (version 13.0; SPSS, Chicago, IL, USA); P < 0.05 was considered significant, and all statistical tests were two-sided.
Results
Study population and demographic characteristics
The baseline demographic characteristics of the study population are shown in Table 1 . Overall, the mean age of the mothers at the time of entry into the MABC was 26.55 years (range 18-44), and most mothers were prepared for pregnancy (85.1%). Most women were giving birth for the first time (90.2%), and some of the participants reported snoring in their sleep before pregnancy (25.8%). The mean birthweight was 3.37 kg (range 1.15-4.92). We observed that mothers with higher pre-pregnancy BMI and GWG had a higher risk for LGA offspring. Fetal gender was significantly different in the SGA/LGA group compared with that in the AGA group.
Among the 3178 pairs of mothers and their newborns in our study, 2.5% (78/3080) were defined as IMH in the first trimester and 2.5% (74/2999) in the second trimester. In addition, 12.1% (372/3078) were TPO-Ab positive in the first trimester and 6.8% (204/2999) in the second trimester. Moreover, 9.6% (306/3178) of the infants included in the study were defined as SGA and 16.5% (524/3178) as LGA.
Maternal serum TH levels and birthweight, SGA, and LGA
The measured concentrations of TSH, FT4 and TPO-Ab were as follow: first trimester, 0.01-3.74 uIU/ml, 4.79-7.63 pmol/l and 3.54-89.80 IU/ml, respectively; and second trimester, 0.01-21.61 uIU/ml, 6.98-33.58 pmol/l and 3.54-600.00 IU/ml, respectively. The limits of detection were 0.01 uIU/mL for TSH, 0.30 pmol/l for FT4 and 5.0 IU/mL for TPO-Ab. The series of normal trimester-specific TH reference intervals for TSH and FT4 (median and 2.5th and 97.5th percentiles) are presented in Table 2 . A significant moderate correlation was observed between the first and second trimester for both TSH (r = 0.510, P < 0.01) and FT4 (r = 0.507, P < 0.01).
The association between TH levels and birthweight, SGA and LGA are presented in Table 3 . We found that the maternal serum FT4 level was inversely associated with birthweight and positively associated with the risk of LGA. Crude linear regression models showed that a 1-pmol/l increase in maternal serum FT4 during the second trimester was associated with a 0.029-kg decrease in the birthweight (95% CI: À0.039 to À0.020). These associations remained significant after correcting for potential confounders (b: À0.012, 95% CI: À0.021 to À0.003). In the second trimester, the maternal serum FT4 level was positively associated with LGA (crude models: OR: 0.847, 95% CI: 0.794-0.903; adjusted models: OR = 0.924, 95% CI: 0.862-0.991). We found that TSH decreased the birthweight after adjusting for potential confounders (first trimester: b: À0.017, 95% CI: À0.029 to À0.005; second trimester: b: À0.015, 95% CI: À0.028 to À0.003) but was not associated with the risk of SGA/LGA. TPO-Ab positivity conferred an increased risk of SGA in both the crude (OR: 1.676, 95% CI: 1.093-2.569) and adjusted (OR: 2.122, 95% CI: 1.349-3.336) logistic regression models.
IMH during pregnancy and the risk of SGA/LGA IMH women are prone to exhibit advanced age, a higher BMI before pregnancy, a higher risk of metabolic dysfunctions and more parity (Supporting Information Table S1 ). Given that TPO-Ab positivity has an impact on birthweight, we performed an analysis restricted to the TPOAb-negative women to reveal the sole effect of IMH on LGA/SGA. Compared with AGA, a consistently positive association was observed between IMH and LGA throughout the first and second trimesters, whereas associations between IMH and SGA were null ( 
Discussion
Main findings
In this large population-based study, we found no associations between IMH mothers and SGA offspring. In contrast, we observed a significant inverse association between the maternal serum FT4 level and birthweight, an adverse effect of maternal TPO-Ab positivity on birthweight, and a significantly increased risk of LGA elicited by IMH. These results suggest that higher maternal serum FT4 levels might alter fetal growth and development in the womb, thereby decreasing fetal weight gain.
Strengths and limitations
Our findings contribute information to the literature regarding the adverse effect of lower maternal FT4 levels on fetal growth, which potentially cause a higher risk for offspring impairment associated with IMH and LGA. This large population-based prospective birth cohort study enabled us to consider various important confounding factors, including socio-economic factors and maternal factors. Importantly, we considered the maternal TPO-Ab status and metabolic dysfunction. Finally, our study is one of few to focus on IMH during the prenatal period with respect to pregnancy complications. One limitation of the present study is that iodine concentrations were absent. Iodine deficiency affects not only maternal but also fetal TH production. 3 Ma'anshan is an iodine-sufficient geographical area, and China has implemented a salt iodis ation policy to ensure that residents remain iodine-sufficient since 1996.
Interpretation
Previous epidemiological studies have investigated potential IMH-associated alterations in birthweight. 2, 14, 16, 17 A recent large cohort study from Rotterdam indicated that among euthyroid women, a high FT4 level but not TSH level, is related to SGA. 2 Results from a Spanish cohort study indicated that high FT4 levels are associated with an increased risk of SGA, and IMH is associated with higher birthweight compared with that in the context of euthyroid. 14 Our results suggest that higher FT4 levels decrease the birthweight and are inversely associated with the risk of LGA. However, Casey et al. 16 found that IMH is not associated with the risk of LGA. Our study revealed that IMH during pregnancy is not associated with SGA, which is consistent with prior reports. In Canada, Hamm et al. 17 demonstrated that IMH during pregnancy (15-16 weeks of pregnancy) is not associated with having an SGA infant. Similarly, Breathnach et al. 21 in Ireland reported that IMH in the early second trimester (mean gestational age 14 weeks) is not associated with intrauterine growth restriction (IUGR). More recently, Ong et al. 18 in Australia reported that IMH in the first trimester is not associated with SGA. In USA, Casey et al. 16 previously reported a similar finding, confirming that IMH in the first half of pregnancy is not associated with low birthweight. Conversely, data obtained by Su et al. 15 suggest that infants of IMH mothers (in the first 20 weeks of pregnancy) are at a greater risk of SGA and fetal distress. This discrepancy might be explained by sample sizes, epidemiological study designs, the timing of serum collection, gestational ages of the investigated participants, cut-off criteria for defining IMH, maternal TPO-Ab status, maternal iodine status and GWG. In addition, it could be attributed to a failure of some studies to account for maternal metabolic dysfunction, whereas our study controlled for gestational diabetes mellitus, diabetes mellitus-complicated pregnancy and other metabolic dysfunctions during pregnancy. In addition, the results might differ because some other studies treated birthweights continuously, whereas in the present study, birthweights were also categoris ed as SGA, AGA or LGA.
Successful animal models of IMH have been developed but most of these models are focused on the neurodevelopment of progeny rather than fetal growth. Although the potential mechanisms remain undetermined, IMH in pregnant women might play a major role in birthweight. Thyroid organogenesis remains an unknown process characteris ed by the complex integration of multiple factors. 22 Even mild alterations in the circulating TH levels during pregnancy may have important implications for fetal health.
19 TH4 is the major TH in the thyroid gland and in the circulation. TH is critical for normal fetal development 3 and acts directly on fetal metabolism through anabolic effects. 23 The human placenta regulates the quantity and composition of different forms of transported TH to ensure that the requisite levels are present in the fetus for each stage of development. 24 Therefore, maternal thyroid dysfunction can theoretically cause LGA via both maternal and placental mechanisms. 8 Our findings provide new insights for further research exploring the impact of IMH on altered birthweights.
Our current study is one of the few to investigate the relation between maternal TPO-Ab status and birthweight. Our results suggest that TPO-Ab positivity in the second trimester increases the risk of SGA. However, the existing evidence might not indicate a conclusion on the role of TPO-Ab status on the risk of SGA. For example, Medici et al. 2 indicated no associations between early pregnancy maternal TPO-Ab positivity and low birthweight. Ong et al. 18 in Australia suggested that TPO-Ab positivity does not increase the risk of SGA, which is consistent with another study conducted by Monen et al. 25 However, the results from the Northern Finland Birth Cohort (NFBC) 26 showed that TPO-Ab-positive mothers are more susceptible to having both low-birthweight and LGA infants than are TPO-Ab-negative mothers. TPO-Ab positivity might be a risk factor for birth outcomes, but TPO antibodies themselves could also have an independent effect. 26 From our perspective, the effect of TPO-Ab status on birthweight must be considered when exploring the association between TH levels and birthweight, SGA and LGA.
In this large population-based cohort study, our results revealed that the prevalence of IMH is 2.5% in both the first and second trimesters. The overall prevalence of IMH is consistent with that reported in previous studies in China (2.1-2.4%). 5, 27 However, the prevalence of IMH in this study is higher than that in the UK (1.6%) 28 and USA (1.3-2.3%), 16, 29 and lower than that in the Netherlands (4.3-8.5%), 30 Thailand (8.4%), 31 Italy (3.2-12.7%) 32 and Spain (20.6-26.5%). 33 Most studies used a lower FT4 cutoff value (2.5th percentile), except for the Netherlands (5th and 10th percentile) and Spain (10th percentile). The incidence rates of IMH vary widely among these studies, which might be explained, in part, by heterogeneity in the diagnostic criteria, the timing of blood sampling during pregnancy, and the iodine nutrition status of the population under examination. 34 However, despite the high prevalence of IMH and its potential harm to fetal growth, there is at present no evidence that the treatment of IMH during pregnancy results in improved outcomes in offspring later in life. Therefore, a large-scale randomised clinical intervention trial is required to determine whether widespread prenatal screening and treatment for maternal thyroid disorders should be implemented.
Conclusions
Our study provides evidence that IMH is associated with a significantly increased risk for LGA infants. This study does not provide evidence to support the notion that IMH increases the risk of SGA. Furthermore, maternal TPO-Ab positivity status is a risk factor for SGA, which provides a new perspective on thyroid dysfunction.
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